Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature

P. A. Phillips, J. Risvanis, K. Aldred, L. M. Burrell, B. Bartholomeusz

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


1. We studied the effects of the non-selective, non-peptide, orally active endothelin (ET) receptor antagonist bosentan (Ro 47-0203) on rat hepatic and mesenteric vascular membrane 125I-ET-1 binding characteristics in vitro and ex vivo (after bosentan by gavage in vivo). 2. Bosentan caused a concentration-dependent competitive inhibition of 125I-ET-1 binding to female rat mesenteric vascular (predominantly ETA receptors) and hepatic (predominantly ETA receptors) membranes in vitro and ex vivo. 3. The time course of the inhibition of binding ex vivo after administration of bosentan in vivo was 1-4 h for mesenteric vascular (predominantly ETA receptors) binding and 1-16 h for hepatic (predominantly ETA receptors) binding. 4. The time course of displacement of 125I-ET-1 binding from mesenteric vascular and hepatic membranes by bosentan in vitro was similar. 5. Since bosentan is significantly excreted by the liver, the prolonged hepatic 125I-ET-1 binding by bosentan presumably represents hepatic accumulation of bosentan, which may have implications for bosentan antagonizing the actions of ET in the liver.

Original languageEnglish
Pages (from-to)575-579
Number of pages5
JournalClinical Science
Issue number6
Publication statusPublished - 1 Dec 1995
Externally publishedYes


  • Antagonists
  • Bosentan
  • Endothelin
  • Hypertension
  • Liver
  • Receptors


Dive into the research topics of 'Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature'. Together they form a unique fingerprint.

Cite this